ストックスクリーナーアプリを入手
3.41
0.58%
-0.02
アフターアワーズ：
3.35
-0.06
-1.76%
前日終値:
$3.43
開ける：
$3.42
24時間の取引高:
247.81K
Relative Volume:
0.62
時価総額：
$33.32M
収益：
-
当期純損益:
$-23.87M
株価収益率:
-0.1734
EPS:
-19.67
ネットキャッシュフロー:
$-47.63M
1週間 パフォーマンス:
+4.28%
1か月 パフォーマンス:
+25.83%
6か月 パフォーマンス:
+30.65%
1年 パフォーマンス:
-20.70%
1日の値動き範囲:
$3.3307
$3.475
1週間の範囲:
$2.77
$3.93
52週間の値動き範囲:
$2.30
$4.49
Polypid Ltd Stock (PYPD) Company Profile
PYPD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.41 | 33.32M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | 開始されました | Roth Capital | Buy |
| 2025-06-02 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2021-09-14 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-07-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 開始されました | Alliance Global Partners | Buy |
| 2020-07-21 | 開始されました | BMO Capital Markets | Outperform |
| 2020-07-21 | 開始されました | Barclays | Overweight |
| 2020-07-21 | 開始されました | Raymond James | Outperform |
すべてを表示
Polypid Ltd (PYPD) 最新ニュース
FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PESG Research Update: PolyPid SHIELD’s II Delivers - GlobeNewswire
PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline ResultsParadigm Shift in Surgical Infection Prevention - Yahoo
In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed - insights.citeline.com
HC Wainwright Issues Positive Forecast for PolyPid (NASDAQ:PYPD) Stock Price - Defense World
PolyPid reports positive phase 3 surgical infection drug trial - גלובס
PolyPid (PYPD) Target Price Increased as Phase 3 Trial Data Impr - GuruFocus
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial - Benzinga
PolyPid shares surge on successful D-PLEX100 trial results By Investing.com - Investing.com South Africa
PolyPid shares surge on successful D-PLEX100 trial results - Investing.com Australia
Transcript : PolyPid Ltd.Special Call - marketscreener.com
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - The Manila Times
PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial - marketscreener.com
PolyPid (PYPD) Reports Positive Phase 3 Trial Results for D-PLEX100 | PYPD Stock News - GuruFocus
PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial - TipRanks
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewswire
What is Roth Capital’s Forecast for PolyPid Q2 Earnings? - Defense World
Roth Capital Begins Coverage on PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - The Manila Times
PolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100 - Nasdaq
PolyPid to Host Conference Call and Webcast to Discuss - GlobeNewswire
Major Clinical Trial Results: PolyPid's D-PLEX100 Shows New Data for Preventing Post-Surgery Infections - Stock Titan
Roth Capital Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - Nasdaq
Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rat - GuruFocus
Roth Capital Initiates Coverage on PolyPid (PYPD) with a Buy Rating | PYPD Stock News - GuruFocus
Roth Capital Initiates PolyPid at Buy With $9 Price Target - marketscreener.com
PolyPid initiated with a Buy at Roth Capital - TipRanks
What is HC Wainwright’s Forecast for PolyPid Q2 Earnings? - Defense World
FY2027 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Upgraded by HC Wainwright to “Buy” Rating - Defense World
PolyPid (NASDAQ:PYPD) Now Covered by HC Wainwright - Defense World
Wall Street Analyst Says PolyPid is a Buy with 300% Potential Upside as it nears Phase 3 Data Readout - newsblaze.com
PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Through Clinical Trials to Improve Surgical Outcomes, Enhance Treatment Efficacy, Minimize Side Effects - Yahoo Finance
H.C. Wainwright assumes coverage on PolyPid stock with buy rating - Investing.com
PolyPid assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright assumes coverage on PolyPid stock with buy rating By Investing.com - Investing.com India
PolyPid (PYPD) Receives a 'Buy' Rating from HC Wainwright & Co. - GuruFocus
H.C. Wainwright Initiates Buy Coverage on PolyPid (PYPD) with $1 - GuruFocus
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - Defense World
PolyPid Expands Share Option Plan to Boost Stakeholder Engagement - TipRanks
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid’s D-PLEX100 Approaches Critical Phase 3 Data Readout - Yahoo Finance
PolyPid at Lytham Partners: Strategic Advances and Financial Stability - Investing.com India
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call Transcript - MSN
PolyPid chairman to step down at June shareholder meeting By Investing.com - Investing.com Nigeria
PolyPid chairman to step down at June shareholder meeting - Investing.com Australia
PolyPid Announces Leadership Changes Ahead of June 2025 Shareholder Meeting - TipRanks
PolyPid Opens Virtual Access to Investors: Key Presentation and 1-on-1 Meetings at Lytham Conference - Stock Titan
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - GlobeNewswire
Head to Head Survey: PolyPid (NASDAQ:PYPD) & Lombard Medical (OTCMKTS:EVARF) - Defense World
Tenon Medical (NASDAQ:TNON) vs. PolyPid (NASDAQ:PYPD) Critical Comparison - Defense World
Polypid Ltd (PYPD) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):